A prospective, randomized, double-blind trial recently demonstrated that treating @entity1 with @entity740 with @entity2815 significantly decelerates the rate of progression of the disease. We tested the hypothesis that preventative treatment with the @entity1289 ( @entity1289 ) inhibitor @entity2815 in @entity1 with @entity740 is cost-effective. A Markov chain model was used that considered regular treatment, hemodialysis, continuous ambulant peritoneal dialysis, transplantation, rejection and death. Clinical trial data were used to estimate the effects of @entity2815 treatment and to estimate the duration until renal replacement therapy was needed. Epidemiologic parameters were derived on the basis of Dutch registries of @entity8 , costs are estimated by updating former estimates, literature review and expert opinion. We found that preventative treatment with @entity2815 decreased the percentage of @entity1 who died or developed @entity454 . Total costs per @entity1 are expected to decrease in three years with more than  4,000 US per @entity1 . Extrapolated to ten years, the savings are estimated at  23,500 US per @entity1 . @entity2815 treatment is not only an effective treatment in @entity1 with @entity177 . By increasing the years spent without dialysis, it is also a cost-effective treatment.

Economic evaluation of @entity2815 in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal diseases'] @entity1289 :: ('1636', 'Gene') :: ['angiotensin converting enzyme', 'ACE'] @entity740 :: ('MESH:D051436', 'Disease') :: ['chronic renal insufficiency'] @entity2815 :: ('MESH:C044946', 'Chemical') :: ['benazepril', 'Benazepril'] @entity177 :: ('MESH:D051437', 'Disease') :: ['chronic renal failure'] @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease']
@entity740 :: (MESH:D051436,Disease) :: ['chronic renal insufficiency']
